

TABLE OF CONTENTS

INTRODUCTION	1
1. DEFINITION OF MEDICINAL PRODUCTS	3
1.1. INTRODUCTION	3
1.2. THE DEFINITION OF A MEDICINAL PRODUCT IN COMMUNITY LAW	4
1.3. MEDICINAL PRODUCT ACCORDING TO THE PRESENTATION CRITERION	5
1.4. MEDICINAL PRODUCT ACCORDING TO THE FUNCTION CRITERION	8
1.5. MEDICINAL PRODUCTS DERIVED FROM COSMETICS AND FOODSTUFF	11
1.6. THE APPRECIATION OF THE MEMBER STATES UNDER PRESSURE.....	14
2. RESEARCH AND DEVELOPMENT OF MEDICINAL PRODUCTS: CLINICAL TRIALS	17
2.1. NECESSITY OF CLINICAL TRIALS	17
2.2. CLINICAL TRIALS.....	18
2.2.1. <i>Definition of Clinical Trials</i>	18
2.2.2. <i>European Rules on Clinical Trials</i>	20
2.2.2.1. Good Clinical Practices.....	20
2.2.2.2. Proposal for a European Parliament and Council Directive	21
2.2.2.3. Biomedicine Convention.....	25
2.2.3. <i>National Legislation of Some Member States</i>	27
2.3. NECESSARY CONDITIONS FOR THE LEGITIMACY OF CLINICAL TRIAL	28
2.3.1. <i>Scientific Soundness</i>	29
2.3.2. <i>Risk/Benefit Ratio</i>	29
2.3.3. <i>Subsidiarity</i>	29
2.3.4. <i>Free and Informed Consent</i>	30
2.3.4.1. Content.....	30
2.4. REVIEW BY ETHICAL COMMITTEES	30
2.4.1. <i>Formation</i>	30
2.4.2. <i>Tasks</i>	31
2.4.2.1. A Priori Approval.....	31
2.4.2.2. Control	32
2.4.3. <i>Responsibility</i>	32
2.5. CONFIDENTIALITY	32
2.6. PRACTICAL SUGGESTIONS FOR AN INVESTIGATION AGREEMENT	33
2.6.1. <i>Form</i>	33
2.6.2. <i>Content</i>	33
2.6.3. <i>Payment</i>	33
2.6.4. <i>Responsibility</i>	34
2.7. CONCLUSIONS	34
3. MARKETING AUTHORISATION OF A MEDICINAL PRODUCT ...	37
3.1. INTRODUCTION	37
3.2. THE NATIONAL MARKETING AUTHORISATION PROCEDURE.....	37
3.2.1. <i>Standard Procedure to place Medicinal Products on the Market</i>	37
3.2.2. <i>The Progress towards the Harmonisation of Pharmaceutical Law</i> . 38	
3.2.2.1. Standards to Perform Clinical Trials	38

3.2.2.2. The Committee for Proprietary Medicinal Products.....	39
3.2.2.3. From a Multi-state and Concertation Procedure to a Community Procedure	40
3.3. COMMUNITY PROCEDURES FOR A MARKETING AUTHORISATION	40
3.3.1. <i>The Centralised Procedure</i>	41
3.3.1.1. In General.....	41
3.3.1.2. Scope of the Regulation	42
3.3.1.3. Filing an Application to Market	43
3.3.1.4. A Community Decision.....	44
3.3.2. <i>The Mutual Recognition Procedure or the Decentralised Procedure</i>	45
3.3.2.1. The Marketing Authorisation Holder initiates the Procedure.....	45
3.3.2.2. Member State asks for the Procedure.....	46
3.3.3. <i>Community Referrals</i>	47
3.3.3.1. Grounds for Referral	47
3.3.3.2. The Arbitration Procedure.....	48
3.3.3.3. Commission and Council Decision and its implementation by Member States.....	48
3.4. THE ABRIDGED PROCEDURE.....	49
3.4.1. <i>The Emergence of the Abridged Procedure</i>	49
3.4.2. <i>Article 4, 8 of Directive 65/65/EEC and Exemptions to the Principle of Providing Full Test Results</i>	50
3.4.3. <i>Article 4, 8, a, iii of the Directive 65/65 EEC and Confidential Information</i>	52
3.4.4. <i>Article 4, 8, a, iii of the Directive 65/65/EEC and Impact of Original Authorisation on Me-too Applicant</i>	53
3.4.5. <i>Article 4, 8, a, iii of the Directive 65/65 EEC and interpretation of Essential Similarity</i>	54
3.5. VARIATIONS TO THE TERMS OF A MARKETING AUTHORISATION.....	55
3.6. OTHER AUTHORISATIONS.....	57
3.6.1. <i>Marketing authorisations for specific products</i>	57
3.6.1.1. Homeopathic medicinal products.....	57
3.6.1.2. Radiopharmaceuticals	58
3.6.1.3. Medicinal products derived from human blood or human plasma	58
3.6.1.4. Orphan medicinal products	59
3.6.1.5. Parallel Imports	59
3.6.2. <i>Labelling changes</i>	60
3.6.3. <i>Application for renewal of an authorisation</i>	60
3.6.4. <i>Manufacturing authorisation</i>	60
4. DISTRIBUTION OF MEDICINAL PRODUCTS.....	63
4.1. INTRODUCTION	63
4.2. DISTRIBUTION OF MEDICINAL PRODUCTS AND EC COMPETITION LAW... 64	64
4.2.1. <i>Article 81, 1 of the EC Treaty</i>	64
4.2.1.1. Article 81, 1 of the EC Treaty: the Principle	64
4.2.1.1.1. The Notion "agreement"	64
4.2.1.1.2. Agreements of Minor Importance.....	65
4.2.1.2. An Appreciable Restriction under Article 81, 1 of the Treaty	65
4.2.2. <i>Article 81, 3 of the EC Treaty and the Block Exemption Regulations</i>	66
4.2.2.1. Article 81, 3 of the Treaty: the Principle.....	66

4.2.2.2. Commission Regulation No 2790/1999	67
4.2.2.2.1. Scope of the Regulation	67
4.2.2.2.2. The Regulation's Relationship with Existing Block Exemptions	68
4.2.2.2.3. The Exemption.....	69
4.2.2.2.3.1. The Relevant Product and Geographic Markets	70
4.2.2.2.3.2. The Relevant Product Market for Medicinal Products	70
4.2.2.2.3.3. The Relevant Geographic Market for Medicinal Products	72
4.2.2.2.4. Blacklist Clauses.....	73
4.2.3. <i>Article 82 of the EC Treaty</i>	74
4.2.3.1. Dominant Position.....	75
4.2.3.2. Abuse of a Dominant Position.....	75
4.2.4. <i>Vertical Restraints in Distribution Agreements for Medicinal Products</i>	76
4.2.4.1. Export Restrictions	76
4.2.4.2. Dual Pricing Systems and Discount Practices	77
4.2.4.3. Resale Price Maintenance	77
4.2.4.4. Resale Restrictions	78
4.2.4.5. Restrictions on Use	79
4.2.4.6. Refusal to Supply	80
4.3. GOOD DISTRIBUTION PRACTICE OF MEDICINAL PRODUCTS	81
4.3.1. <i>Quality Control</i>	81
4.3.2. <i>Wholesale Distribution of Medicinal Products</i>	81
4.3.2.1. Authorisation for Wholesale Distribution of Medicinal Products	81
4.3.2.2. Personnel.....	82
4.3.2.3. Documentation	82
4.3.2.4. Premises and Equipment	83
4.3.2.5. Returns and Recalls.....	83
4.4. CONCLUSION	84

5. GENERAL INTELLECTUAL PROPERTY ASPECTS AND MEDICINAL PRODUCTS..... 85

5.1. OVERVIEW.....	85
5.2. PATENT LAW	85
5.2.1. <i>Definition and Context</i>	85
5.2.2. <i>Patentable Inventions</i>	85
5.2.2.1. What is a Patentable Invention?	85
5.2.2.2. Different Types of Patents.....	86
5.2.2.3. Legal Exclusions and Exceptions.....	86
5.2.3. <i>Filing and Prosecution</i>	89
5.2.4. <i>Duration</i>	91
5.2.5. <i>Costs and Fees</i>	91
5.2.6. <i>Rights and Infringement</i>	91
5.2.7. <i>Overview of International Jurisdictional Issues</i>	92
5.2.8. <i>Remedies</i>	95
5.2.9. <i>Supplementary Protection Certificates</i>	96
5.3. TRADEMARK LAW	99
5.3.1. <i>Definition and Context</i>	99
5.3.2. <i>Which Kinds of Signs may be Protected?</i>	100
5.3.3. <i>How to get TM Protection?</i>	101
5.3.4. <i>The Costs of Obtaining and Maintaining the Protection</i>	102
5.3.5. <i>Duration of Trademark Protection</i>	102

5.3.6. <i>Infringement</i>	103
5.3.7. <i>Remedies</i>	104
5.4. COPYRIGHT LAW	104
5.4.1. <i>Definition</i>	104
5.4.2. <i>What Works enjoy Copyright?</i>	104
5.4.3. <i>Ownership</i>	105
5.4.4. <i>No Requirement to File or Register</i>	105
5.4.5. <i>No Costs</i>	105
5.4.6. <i>Duration</i>	105
5.4.7. <i>Rights and Infringement</i>	105
5.5. SUPPLEMENTARY MEASURES FOR PROTECTING PATENTS, TRADEMARKS AND COPYRIGHT: THE BORDER CONTROL MEASURES.....	106
5.6. OTHER POSSIBLE PROTECTION	106
6. PARALLEL IMPORT OF MEDICINAL PRODUCTS	107
6.1. INTRODUCTION	107
6.2. INTELLECTUAL PROPERTY RIGHTS	108
6.2.1. <i>The Principle of Exhaustion of Intellectual Property Rights</i>	108
6.2.2. <i>Patents</i>	108
6.2.3. <i>Trademarks</i>	111
6.2.3.1. Directive 89/104/EEC: Community-wide or International Exhaustion?	112
6.2.3.2. <i>Repackaging</i>	113
6.2.3.2.1. Case Law before Directive 89/104/EEC	114
6.2.3.2.2. Directive 89/104/EEC.....	115
6.3. MARKETING AUTHORISATION	117
6.3.1. <i>Directive 65/65/EEC: The Principle</i>	117
6.3.2. <i>Directive 65/65/EEC: Procedures and Case Law</i>	118
6.3.2.1. The Abridged Procedure	118
6.3.2.2. Parallel Import.....	119
7. PATIENT INFORMATION LEAFLETS AND LABELLING REQUIREMENTS	123
7.1. THE IMPORTANCE OF PATIENT INFORMATION	123
7.2. EUROPEAN REGULATORY FRAMEWORK	123
7.2.1. <i>From a Variety of Rules to a Harmonisation</i>	123
7.2.1.1. A Variety of Different Rules	123
7.2.1.2. To a Harmonisation.....	124
7.2.2. <i>Labelling and Package Leaflet Requirements</i>	125
7.2.2.1. Labelling Requirements	125
7.2.2.2. Package Leaflets	127
7.2.2.3. Common Requirements.....	128
7.2.3. <i>Useful Recommendations for Obtaining a Marketing Authorisation</i>	129
7.2.3.1. Guideline on the Excipients in the Label and Package Leaflets of Medicinal Products for Human Use	130
7.2.3.2. Guideline on the Packaging Information of Medicinal Products for Human Use authorised by the Community	131
7.2.3.3. Guideline on the Readability of the Label and Package Leaflet of Medicinal Products for Human Use	134

7.2.4. Conclusion.....	134
7.3. PRACTICAL IMPLICATIONS.....	135
7.3.1. Liability for not Warning the Patient?.....	135
7.3.2. Exception on the Information Obligation for Therapeutic Reasons	136
7.3.3. Prescription or Marketing of a Medicinal Product Based on an Indication not Mentioned on the Packaging.....	138
7.3.3.1. Prescription of Medicinal Products.....	138
7.3.3.2. Marketing of Medicinal Products.....	138
7.3.4. Reuse of Medical Devices.....	139
8. LEGAL ISSUES RELATING TO ECOMMERCE IN THE EUROPEAN HEALTH-CARE SECTOR.....	143
8.1. INTRODUCTION.....	143
8.2. APPLICABLE LAW.....	144
8.3. ESTABLISHMENT OF PROVIDERS OF INFORMATION SOCIETY SERVICES.....	146
8.4. FREE MOVEMENT OF INFORMATION SOCIETY SERVICES.....	147
8.5. THE PROVISION OF HEALTH-RELATED INFORMATION ON-LINE.....	147
8.6. ADVERTISING OF MEDICINAL PRODUCTS.....	149
8.7. DISTRIBUTION OF MEDICINAL PRODUCTS.....	152
8.8. ELECTRONIC CONTRACTS.....	153
8.9. JURISDICTION OF COURTS.....	154
8.10. CONCLUSION.....	155
9. PRICING AND REIMBURSEMENT ISSUES OF MEDICINAL PRODUCTS.....	159
9.1. INTRODUCTION.....	159
9.2. CONTROL OF PRICES AND THE FREE MOVEMENT OF MEDICINAL PRODUCTS	159
9.3. DIRECTIVE 89/105/EEC AND THE PRICE OF A MEDICINAL PRODUCT	161
9.4. DIRECTIVE 89/105/EEC AND REIMBURSEMENT OF A MEDICINAL PRODUCT	163
10. THE PROCESSING OF PERSONAL DATA IN THE PHARMACEUTICAL INDUSTRY.....	165
10.1. INTRODUCTION.....	165
10.2. WHY A PRIVACY DIRECTIVE?.....	166
10.3. FIELD OF APPLICATION OF THE PRIVACY DIRECTIVE.....	166
10.4. DATA QUALITY AND THE NEED FOR LEGITIMATE PROCESSING.....	169
10.5. INFORMING THE DATA SUBJECT AND INFORMED CONSENT.....	170
10.6. RIGHT OF ACCESS, RIGHT TO CORRECT AND RIGHT TO OBJECT.....	171
10.7. SPECIFIC RULES ON PROCESSING HEALTH AND OTHER SENSITIVE DATA IN THE PHARMACEUTICAL INDUSTRY.....	171
10.8. EXAMPLES OF COMMON PROCESSING IN THE PHARMACEUTICAL INDUSTRY.....	172
10.8.1. Personnel/Employee Administration and data on investigators..	172
10.8.2. Administration of Visitors.....	173
10.8.3. Direct Marketing by a Pharmaceutical Company and Data of Prescribing Physicians.....	173

10.8.4. Processing for Research Purposes	173
10.8.5. Processing for Post Marketing Research, Drug Safety, Pharmacovigilance, Drug Utilisation Review and Pharmacoeconomics	176
10.9. CONFIDENTIALITY AND SECURITY MEASURES	177
10.10. NOTIFICATION	178
10.11. TRANSFER OF DATA.....	178
11. LEGAL ISSUES OF THE EXERCISE OF PHARMACISTS	181
11.1. CERTIFICATE OF PHARMACIST	181
11.2. SPECIALISATIONS IN PHARMACY	182
11.2.1. The Industry Pharmacist.....	182
11.2.2. The Hospital Pharmacist	183
11.2.3. The Pharmacist-Specialist in Bioclinical Analyses.....	183
11.3. THE MONOPOLY OF THE PHARMACIST AND EXCEPTIONS	184
11.3.1. Monopoly	184
11.3.2. The Exceptions on the Monopoly.....	184
11.3.2.1. A Limited Delivery	185
11.3.2.2. The Origin of Medicinal Products	185
11.4. THE RULES ON THE OPENING OF NEW PHARMACIES	186
11.5. SUBSTITUTION OF MEDICINAL PRODUCTS	187
11.6. PRICE REDUCTIONS FOR THE PUBLIC	189
11.6.1. The Price Regulation	189
11.6.2. Article 10 of the Law of 25 March 1964 on Medicinal Products.	189
11.6.3. The View of the Council of Pharmacists.....	190